Epidemiological shifts in opportunistic and nosocomial Candida infections: Mycological aspects

International Journal of Antimicrobial Agents

Volumn 6, Issue 3, 1996, Pages 141-144

  Odds, Frank C ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Azole resistance; Candida; Pathogen shift

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; KETOCONAZOLE;

ANTIBIOTIC RESISTANCE; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; CONFERENCE PAPER; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PREVALENCE; PRIORITY JOURNAL; RISK;

EID: 0029866007     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-8579(95)00049-6     Document Type: Conference Paper

References (39)

1. Pfaller M, Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992;11:287-291.
2. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994;38:1422-1424.
3. Wingard JR, Merz WG, Rinaldi MG, John TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New Engl J Med 1991;325:1274-1277.
4. Coste T, Barale T, Reboux G et al. Prophylaxie antifungique par fluconazole: son influence sur l'augmentation de la fréquence d'isolement de Candida glabrata. Bull Soc Fr Mycol Méd 1990;19:151-154.
5. Just-Nubling G, Gentschew G, Dohle M, Bottinger C, Helm EB, Stille W. Fluconazole in the treatment of oropharyngeal candidosis in HIV-positive patients. Mycoses 1990;33:435-440.
6. Millon L, Manteaux A, Reboux G et al. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol 1994;1115-1118.
7. Chavanet P, Lopez J, Grappin M et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro in vivo correlations in HIV-infected patients. AIDS 1994;8:945-950.
8. Dupont B. Resistance trends in oral Candida infections: the clinical challenge. Clinician 1993;11:19-22.
9. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in-vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993;37:2449-2453.
10. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. Antimicrob Agents Chemother 1994;32:2092-2098.
11. Baily GG, Perry FM, Denning DW, Mandal BK. Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994;8:787-792.
12. Willocks L, Leen CLS, Brettle RP, Urquhart D, Russell TB, Milne LJR. Fluconazole resistance in AIDS patients. J Antimicrob Chemother 1991;28:937-939.
13. Fox R, Neal KR, Leen CLS, Ellis ME, Mandal BK. Fluconazole resistant Candida in AIDS. J Infect 1991;22:201-204.
14. Denning DW, Ng TTC. Fluconazole-insensitive OPC in AIDS patients. J Infect 1994;28:223-232.
15. Odds FC. Candida and Candidosis (2nd ed). Bailliere Tindall, London 1988.
16. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992;14(suppl 1):S120-S125.
17. Hadfield TJ, Smith MB, Winn RE, Rinaldi MG, Ceuena C. Mycoses caused by Candida lusitaniae. Rev Infect Dis 1987;9:1006-1012.
18. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ. Epidemiology of nosocomial acquisition of Candida lusitaniae. J Clin Microbiol 1992;30:3005-3008.
19. Shepp DH, Klosterman A, Siegel MS, Meyers JD. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis 1985;152:1257-1263.
20. Meunier F. Prevention of mycoses in immunocompromised patients. Rev Infect Dis 1987;9:408-416.
21. Odds FC. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother 1993;31:463-471.
22. Fainstein V, Bodey GP, Elting L, Maksymiuk A, Keating M, McCredie KB. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother 1987;31:11-15.
23. Troke PF. In vitro and experimental in vivo activities of fluconazole against some fungi causing cutaneous mycoses, p. 199-214. In: Rippon JW, Fromtling RA (eds) Cutaneous Antifungal Agents. Marcel Dekker, New York, 1993.
24. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992;326:845-851.
25. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J Antimicrob Chemother 1993;31:973-984.
26. Ellis ME, Clink H, Ernst P et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994;13:3-11.
27. Chandrasekar PH, Gatny CM. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. J Antimicrob Chemother 1994;33:309-318.
28. Akiyama H, Mori S, Tanikawa S, Sakamaki H, Onozawa Y. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies. Mycoses 1993;36:373-378.
29. Ellis ME, Hussain Qadri SM, Spence D et al. The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of Candida spp. from surveillance cultures. J Antimicrob Chemother 1994;33:1223-1228.
30. Van Belkum A, Melchers W, De Pauw BE, Scherer S, Quint W, Meis JF. Genotypic characterization of sequential Candida albicans isolates from fluconazole-treated neutropenic patients. J Infect Dis 1994; 169:1062-1070.
31. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-672.
32. Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
33. Kunová A, Trupl J, Spánik S et al. Candida glabrata, Candida krusei, non-albicans Candida spp., and other fungal organisms in a sixty-bed national cancer center in 1989-1993: no association with the use of fluconazole. Chemotherapy 1995;41:39-44.
34. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115-125.
35. Bart-Delabesse E, Boiron P, Carlotti A, Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol 1993;31:2933-2937.
36. Pfaller MA, Rhine-Chalberg J, Redding SW et al. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 1994;32:59-94.
37. Vuffray A, Durussel C, Boerlin P et al. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS 1994;8:708-709.
38. Odds FC, Bernaerts R. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol 1994;32:1923-1929.
39. Galgiani JN, Bartlett MS, Espinel-Ingroff A, Fromtling RA, Pfaller MA, Rinaldi MG. Reference method for broth dilution antifungal susceptibility testing of yeasts; proposed standard. NCCLS Publ M27-P, NCCLS, Villanova, PA, 1992.